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Abstract. The spontaneously hypertensive rat (SHR) is
an animal model of genetic hypertension which devel-
ops heart failure with aging, similar to man. The
consistent pattern of a long period of stable hypertro-
phy followed by a transition to failure provides a useful
model to study mechanisms of heart failure with aging
and test treatments at differing phases of the disease
process. The transition from compensated hypertrophy
to failure is accompanied by changes in cardiac func-
tion which are associated with altered active and
passive mechanical properties of myocardial tissue;
these events define the physiologic basis for cardiac
decompensation. In examining the mechanism for
myocardial tissue dysfunction, studies have demon-
strated a central role for neurohormonal activation,
and specifically the renin-angiotensin-aldosterone
system. Pharmacologic attenuation of this system at
differing points in the course of the process suggests
that prevention but not reversal of myocardial tissue
dysfunction is possible. The roles of the extracellular
matrix, apoptosis, intracellular calcium, beta-adrener-
gic stimulation, microtubules, and oxygen supply-
demand relationships in ultimately mediating myocar-
dial tissue dysfunction are reviewed. Studies suggest
that while considerable progress has been made in
understanding and treating the transition to failure,
our current state of knowledge is limited in scope and
we are not yet able to define specific mechanisms
responsible for tissue dysfunction. It will be necessary
to integrate information on the roles of newly discov-
ered, and as yet undiscovered, genes and pathways to
provide a clearer understanding of maladaptive re-
modeling seen with heart failure. Understanding the
mechanism for tissue dysfunction is likely to result in
more effective treatments for the prevention and rever-
sal of heart failure with aging. It is anticipated that the
SHR model will assist us in reaching these important
goals.
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Introduction
Age is a leading risk factor for the development of
heart failure in humans. The incidence of heart
failure increases more than 5-fold during the 7th
and 8th decades of life [1]. For Americans over
the age of 65, heart failure is the most common
hospital discharge diagnosis and the most expen-
sive Medicare item. Despite advances in the
treatment of heart failure, pharmacologic thera-
pies for heart failure remain ameliorative rather
than reparative [2]. Considering the projected
increase in the population of aged individuals in
the 21st century, studies of the mechanisms that
contribute to heart failure in the aging human
population are of great interest and importance.
Aging in healthy humans and experimental
animals is associated with changes to the myocar-
dium that reduce the reserve capacity of the
heart to respond to stress [3,4]. These factors
and others contribute, in a poorly understood
manner, to the progression from stable hypertro-
phy to ventricular dysfunction and heart failure
in an aging population. The decompensated, fail-
ing heart is characterized by impaired functional
performance, despite compensatory hypertrophy.
Manifestations of decompensated function
include ventricular dilation, depressed fractional
shortening, and diminished ejection fraction.
Interstitial fibrosis is a hallmark of heart failure
associated with left ventricular hypertrophy
[5–7] as well as normal aging [4,8,9]. Fibrosis
increases the stiffness of the myocardium,
contributing to diastolic dysfunction, and
aggravating heart failure [10].
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While studies in man have defined the effects
of aging and hypertension on morbidity and
mortality, much further work is needed before
we understand the fundamental basis for patho-
logical events. The heterogeneity of human heart
failure and the limited ability to carry out care-
fully controlled studies of mechanisms of heart
failure render studies of humans as inadequate
for solving the problems of heart failure in a
timely manner. The difficulty in obtaining
mechanistic information from studies in
humans provides a strong rationale to study
animal models of heart failure associated with
aging. The spontaneously hypertensive rat (SHR)
develops hypertension and cardiac hypertrophy
during the first quartile of life. Stable, compen-
sated hypertrophy is present for most of its
subsequent lifespan. Male SHRs ultimately
develop cardiac dysfunction and heart failure
between 18–24 months of age [11,12]. Thus, the
SHR may be a useful model to study the transi-
tion from compensated hypertrophy to decompen-
sated heart failure in the context of aging. This
review will focus on studies of the aging SHR
which demonstrate a transition to heart failure.
The Aging SHR Model of Heart Failure
The SHR was originally introduced by Okamoto
and Aoki [13] as a model of genetic hypertension.
It has been pointed out that the progression from
hypertrophy to impaired cardiac function in the
SHR is similar to the clinical course of patients
with hypertension [14]. Persistent hypertension
develops in the SHR after approximately 2
months of age [15,16]. Following a relatively
long period of stable hypertension and compen-
sated hypertrophy, at approximately 18 months
of age, animals begin to develop evidence of
impaired function [11]. Clinically, these rats are
observed to develop tachypnea and labored
respirations. After the age of 18 months, mortal-
ity rate is increased; on pathologic evaluation,
cardiac hypertrophy is found in virtually all SHR.
If animals with tachypnea and labored respira-
tions are studied, all were found to have one or
more of the pathologic features suggesting heart
failure; e.g. effusions, left atrial thrombi and
right ventricular hypertrophy [17]. Findings in
these animals are consistent with observations of
cardiac insufficiency in late stages of pressure
overload in the SHR, associated with impaired
contractility, cardiac chamber dilatation and
fibrosis [18]. Echocardiographic studies and
cardiac catheterization were performed in a
subgroup of animals including those later demon-
strated to have pathological features of failure
(SHR-F) on post mortem examination. In compar-
ison to age matched non-failing SHR (SHR-NF)
and non-hypertensive Wistar-Kyoto rats (WKY),
LV systolic and diastolic chamber dimensions and
filling pressures were increased [12]. In a group
of 63 SHR, 54 (85 %) died or developed heart
failure by 24 months of age. 37 (59 %) had patho-
logic evidence of heart failure at a mean age of
19 2 months [19]. Thus, over 50 % of SHR
develop heart failure over the course of their
lifespan.
Myocardial Function
The relation between the syndrome of heart fail-
ure and mechanical dysfunction of the heart as a
muscle, deduced from catheterization laboratory
or hemodynamic studies in humans, is not
straightforward. Studies in experimental animals
may likewise be difficult to interpret. To more
clearly define the physiologic state of SHR hearts
under study we have characterized the SHR
model of the transition to heart failure using an
integrated approach which includes echocardio-
graphy, cardiac catheterization, isolated perfused
heart studies, isolated papillary muscle studies
and pathological evaluation [12]. Increased
chamber dimensions, elevated filling pressures,
impaired pump function, and pathological find-
ings document clinical heart failure. Isolated
papillary muscle studies provide a direct measure
of the mechanical properties of the myocardium
as a tissue.
Heart failure ultimately results from an
impairment of the pump function of the heart.
This is easily understood in the heart with
impaired muscle function. However, it is impor-
tant to realize that failure may occur in the heart
in which myocardial function is normal but an
excessive load is imposed—load induced heart
failure. A sudden obstruction to flow in a
normal heart—for example—from a pulmonary
embolus, which impedes right ventricular
outflow, may result in acute right ventricular
failure with intrinsically normal right ventricular
muscle function. A common cause of abrupt LV
failure with normal muscle function is sudden or
paroxysmal hypertension. Myocardial infarction
will likewise suddenly augment the load on adja-
cent normal myocardium. It has been suggested
that the transition to failure in the SHR may
reflect an increased load due to a pulsatile contri-
bution to total load, secondary to changes in
conduit vessel function [20]. In an analogous
manner, a reduced ability to develop hypertrophy
might result in a relative increase in load and
heart failure in otherwise normally functioning
myocardium. The work of Gerdes et al. [21]
studying the spontaneously hypertensive heart
failure rat (SHHF) supports this possibility. LV
myocyte cross-sectional area was found to reach
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a maximum by 2–3 months of age. Systolic wall
stress continued to rise and cell length was
increased by 12 months of age while myocyte
cross-sectional area failed to increase. Interest-
ingly, when the hypertrophied RV was studied
from SHHF with heart failure, RV myocyte
length and width increased proportionately [21].
These studies suggest that transverse growth of
the LV myocyte is impaired in the SHHF.
The findings of studies examining contractile
properties from isolated muscle preparations
from the SHR are reviewed below (see also
Table 1). While studies of isolated muscle
preparations have their own set of limitations
which include the need to carry out studies at
low temperatures and low stimulation rates, find-
ings are considered to reflect intrinsic properties
of myocardial tissue. Additional studies of
myocyte function help sort out the role of tissue
components (myocytes, extracellular matrix) as
contributing to cardiac dysfunction and heart
failure. Studies of isolated papillary or trabecular
muscle preparations include a determination of
the active and passive properties of myocardium
in a controlled environment under fixed experi-
mental conditions; i.e., temperature, nutrients,
including dissolved gasses, stimulation rate, and
load. Parameters measured include active
contraction parameters; e.g. active tension (AT),
maximum or mean rate of isometric tension
development (dT=dt) and maximum shortening
velocity measured at minimum load. Temporal
parameters of contraction include electromecha-
nical delay time (EMD), time to peak tension
(TPT), and the time from peak tension to 50 %
tension decline (RT1=2), which is used as an index
of relaxation. The passive properties or stiffness
(k) of the muscle preparation are derived from
measurements of force-length determinations
during passive stretches of the preparation. kcs
is stiffness determined from a central undamaged
segment of the papillary muscle preparation [22].
Using this approach, it has been found that
active properties of isolated papillary muscle
preparations from the SHR at 6, 12 and 18
months are enhanced in comparison to normo-
tensive controls (Fig. 1). AT and dT=dt were found
to be approximately 25 % increased in SHR from
6–18 months of age. Enhanced calcium transients
[23] and contractile state have been reported in
SHR myocytes [24,25]. Shorofsky et al. [26] have
recently reported that calcium sparks linked
to calcium entry through L-type Ca2þ channels
and release of Ca2þ from SR are increased in 6
month old non-failing SHR in association with an
enhanced contractile state. In the 18 month SHR
an increase in TPT was observed [27]; otherwise
myocardial performance was not impaired until
pathological manifestations of heart failure
(including effusions, atrial thrombi and right
ventricular hypertrophy) are present [12]. In
the SHR-F, in comparison to age-matched SHR-
NF and WKY, a depression of active muscle
properties is observed; active tension (Fig. 2,
left), dT=dt and maximum shortening velocity
are depressed. It is interesting that if corrected
for the histological constituents of the myocar-
dium, which are altered as a result of myocyte
loss and fibrosis, the active properties of remain-
ing myocardium may not be impaired. That is,
if calculations of muscle active tension are
corrected for fractional myocyte cross-sectional
area, myocardial active tension is not different
from control [28]. This suggests that depressed
active tension developed by whole papillary
muscles might be explained by a shift in the
composition of the muscle preparation; an
increased portion is made up by non-contracting
material including extracellular matrix compo-
nents, and that the function of remaining
myocytes is relatively unimpaired. Findings are
consonant with studies of myocytes; Emanuel
et al. [29] found no differences in myocyte proper-
ties from failing and non-failing SHR hearts and
concluded that myocyte apoptosis and remodeling
of the extracellular space were more likely
responsible for the development of heart failure.
On the other hand, a study of right ventricular
pressure overload in cats demonstrated impaired
myocyte contractile dysfunction [30]. Differences
may relate to the ventricle (left vs. right), species
studied, or stage of hypertrophy=failure; there-
fore, the critical issue of the basis for impaired
cardiac function observed in heart failure asso-
ciated with chronic pressure overload remains
unresolved.
Fig. 1. Passive and active force (tension)-length
relationships obtained from isolated papillary muscle
preparations from 6, 12 and 18 month old (circles, squares and
triangles, respectively) spontaneously hypertensive (open
symbols) and normotensive rats (closed symbols). Active
tension is increased in the SHR at all ages studied. Lmax is
muscle length at which peak active tension is developed
(adapted from [102]).
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Associated changes in temporal parameters of
contraction include a prolonged TPT which is
seen in both SHR-NF and SHR-F. A prolonged
EM delay time and an abbreviation of the half-
relaxation time are observed only in the SHR-F.
Studies of the passive properties of the myocar-
dium demonstrate an increase in muscle stiffness
(kcs) in the SHR-F, which is associated with
fibrosis determined from histological studies
and collagen determinations (Fig. 2; center,
right) [28].
A consistent finding that has been observed in
studies of failing (but not hypertrophied non-fail-
ing) SHR myocardium is an abbreviated RT1=2
[17,19,28,31]. A similar abbreviation of RT1=2 is
found in preparations from failing hearts from
the aortic banded WKY (unpublished observa-
tions); thus, this is not a strain specific finding.
Traditional thought has been that relaxation is
impaired in cardiac hypertrophy, and further
impaired in failure. Impaired relaxation has
been correlated with molecular data suggesting
impairment of calcium handling, and decreases
in the transcripts of components of the cardiac
relaxing system have been reported in studies of
cardiac hypertrophy and failure.
The finding of an abbreviated RT1=2 in the
SHR-F does not appear consistent with impaired
relaxation, and suggests that biochemical and
molecular findings may not relate directly to
physiologic relaxation in heart failure in the
SHR. Studies of myocardial relaxation in the
intact heart must take into account the multiple
factors that affect cardiac mechanics. Certainly,
an analysis of the time course of in vivo force or
pressure tracings alone is inadequate. Myocar-
dial performance, including both contraction and
relaxation, are considerably affected by loading
conditions. A discussion of the complexities of the
mechanics of contraction and relaxation is
beyond the scope of this review. However, an
understanding of these events is integral to
understanding the relation between mechanical
function and heart failure. A number of mechan-
ical and neurohormonal factors are well recog-
nized to alter the time course of mechanical
activity. Simply increasing afterload will prolong
contraction and relaxation. The finding of
‘‘impaired relaxation’’ based on an examination
of the time course of pressure or stress recordings
after myocardial infarction, for example, may
simply reflect the relative increase in load borne
by surviving myocardium, which must generate
a more isometric and prolonged contraction—
giving the appearance of ‘‘impaired relaxation’’.
A similar analysis of pressure or force traces in
cardiac hypertrophy and failure may yield a
similar erroneous conclusion of ‘‘impaired relaxa-
tion’’. Efforts to develop load independent
measures of relaxation have spawned a number
of indices. Using tau, a load independent measure
of the time course of force decline [32] and a
number of indices to study relaxation in the fail-
ing SHR heart, no evidence for mechanical
impairment of relaxation studying isolated
muscle preparations has been found (unpub-
lished observations).
While mechanical studies of myocardial
relaxation provide empirical information, find-
ings appear to be of limited value in furthering
Fig. 2. Active tension, myocardial stiffness (kcs; central segment stiffness) and fibrosis of papillary muscles from WKY (n¼ 12),
SHR-NF; (n¼ 8) and SHR-F (n¼7). Active tension is depressed while kcs and fibrosis are increased in preparations from the SHR-F
relative to age-matched WKYand SHR-NF. Stiffness is determined from central segments of papillary muscle preparations (adapted
from [28]). ** P< 0.01.
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our understanding of cardiac relaxation in heart
failure. Myocardial relaxation is a complex [33]
multicomponent process. For example, the time
course of calcium release must overlap with that
of calcium uptake; this interaction will affect
relaxation dynamics. In addition to calcium
sequestering mechanisms, the lifetime of cross-
bridge attachment may also affect relaxation. In
the case of ATP depletion, (hypoxia or ischemia),
crossbridges may bind with high affinity at very
low calcium concentrations [34]. Thus, rigor bond
formation may alter the diastolic properties
of myocardium largely independent of [Ca2þ]i.
With respect to calcium handling, it is unclear
how the multiple components of the cardiac
calcium handling system interact to modulate
the contraction-relaxation cycle and how disease
might effect the individual components as well
as their integrated activities. Thus, mechanical
relaxation represents the sum or net of a complex
multicomponent process and the relation of a
change in a relaxation index such as RT½ or tau
to a specific finding such as impaired SR calcium
uptake may be difficult to define.
Prevention and Treatment of Heart
Failure
Considering the well documented clinical=
pathological outcome of long-term studies, the
SHR is a useful model to study therapies aimed
at prevention and treatment of heart failure.
Several treatment studies were carried out to
examine mechanisms of heart failure as well as
to provide pilot data for potential clinical studies.
Studies designed to evaluate prevention of failure
involved administering therapy to SHR and
control animals at 12 and 18 months which is
before the mean age of failure (19 2 months)
and to study animals at 24 months, an age where
there are normally few surviving untreated SHR.
One group of clinically non-failing SHR was
treated at 21 months of age which is beyond the
mean age of failure for the SHR group as a
whole; treatment was carried out to 24 months.
In an attempt to reverse failure, treatment was
initiated in animals with evidence of heart failure.
Echocardiograms were performed on a subgroup
of these animals [12]; LV dilation and reduced
ejection fraction were documented. Treatments
studied in our laboratory to date, in an attempt
to prevent=reverse failure in the SHR, included
the angiotensin converting enzyme inhibitor,
captopril [19], colchicine, which lyses microtu-
bules, suggested to modulate cardiac cytoskeletal
mediated impairment of function [35], L-arginine,
a substrate for NO synthesis, thought to improve
coronary flow and attenuate cardiac fibrosis [36]
and losartan, an AT1 receptor blocker (Lakatta
et al, in preparation).
Outcome parameters included mortality,
pathological data including measures of hyper-
trophy and failure, isolated muscle function,
changes in gene expression and changes in
calcium handling. In brief, these studies demon-
strated no protective effect of colchicine (1 mg=L
drinking water) administered from age 13–24
months [35] or L-arginine (16 g=L drinking
water) administered from 18–24 months [36].
Captopril (2 g=L in drinking water) administered
to SHRs prior to failure beginning at 12, 18 and
21 months until 24 months, totally prevented the
clinical and pathological manifestations of fail-
ure. Although a few captopril treated animals
died before 24 months of age, none was found to
have pathological evidence of failure at autopsy.
Studies of the myocardium from captopril treated
24 month old SHR revealed that in comparison to
SHR-F, depression of papillary muscle active
properties (Fig. 3), myocardial fibrosis and
increased stiffness did not take place [19]. These
findings are generally consonant with those
reported by Tan et al. [37] using lisinopril. In
addition, changes in gene expression associated
with the transition to failure [38] did not occur,
and prolongation of the intracellular calcium
transient associated with hypertrophy and fail-
ure was prevented [39]. In contrast to untreated
SHR, positive inotropic responses of papillary
muscles to isoproterenol were present in SHRs
treated with captopril [19].
It has been theorized that the beneficial effects
of captopril may be due to angiotensin converting
enzyme (ACE) inhibition as well as non-ACE
effects of captopril. In a recent study comparing
captopril with losartan, a specific angiotensin II
receptor (AT1) blocker, protection appeared to be
identical to that observed with captopril (Lakatta
et al., in preparation). Losartan has also been
shown to attenuate the electrophysiological
alterations seen in the old SHR [40]. Therefore,
it appears unnecessary to invoke a role for non-
ACE effects of captopril, at least with respect to
the parameters studied. These data are consis-
tent with the well recognized concept that angio-
tensin II (Ang II) plays a critical role in the
transition to heart failure.
Interestingly, if captopril is administered to
clinically non-failing SHR at 21 months of age
(which is beyond the mean age that failure devel-
ops), significant protection is observed. The slight
decline in performance parameters observed in
animals in which treatment was initiated at
progressively older ages may reflect the presence
of early failure (not detected at the time treat-
ment was initiated) in some of the animals prior
to treatment.
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The overall data suggest that ACE inhibition
(or Ang II blockade), before the advent of failure
prevents clinical and pathological manifestations
of heart failure in the SHR, consistent with the
landmark study in the SHR by Pfeffer and co-
workers [41]. Moreover, of paramount interest
and clinical importance, impairment of intrinsic
myocardial tissue function does not occur. Addi-
tionally, increased myocardial fibrosis, changes in
the intracellular calcium transient, impaired
inotropy to catecholamines and changes in mole-
cular markers associated with failure are not
observed. Swynghedauw et al. [42] reported
converting enzyme inhibitor administration to
middle-aged SHRs reduced hypertension, LVH,
ventricular fibrosis, and ventricular irritability,
and normalized heart rate variability. These
data support the concept of a primary role for
neurohormonal stimulation; specifically angio-
tensin II in the transition to overt failure, and
secondary roles for parameters measured in this
study including fibrosis, altered calcium handling
and changes in expressions of genes encoding
components of these systems. On the other
hand, while these events may occur secondary
to the action of Ang II, their effects may be of
primary importance in contributing to the heart
failure phenotype. Therefore, blocking specific
secondary events may have a therapeutic role.
It is conceivable that not all of the actions of Ang
II in heart failure are detrimental and that inhi-
biting specific components of Ang II actions may
be of greater benefit than total inhibition of Ang
II production or blocking all of its effects.
When captopril was administered to SHR after
clinical and echocardiographic manifestations of
Fig. 3. The effect of no treatment (n¼ 24) and captopril treatment (2 g=L drinking water) on active tension and dT=dt developed by
papillary muscle preparations from SHR. Captopril was begun at 12 (n¼6), 18 (n¼ 12) and 21 (n¼11) months of age and
administered to 24 months. Data from 24 month untreated WKY (n¼10) are shown. Captopril was also administered to a group of
SHR-F (n¼6; mean age 21) months until 24 months and data are compared with untreated SHR-F (n¼ 8). 6 of 12 SHR treated with
captopril after failure survived to 24 months and study. The earlier captopril is administered to SHR the greater the performance of
papillary muscles studied at 24 months. If captopril is administered after failure there is no difference in the performance of
preparations from captopril treated and untreated SHR-F (adapted from [19]).
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failure [19], the clinical course appeared to stabi-
lize; often there was a decrease in respiratory
distress and approximately 50 % of treated
animals survived to 24 months at which time
they were studied. Findings are in general agree-
ment with Secchi et al. [43], who reported a lower
mortality rate in trandolapril and enalapril trea-
ted SHRs with congestive heart failure. Although
clinical manifestations improved, and there was a
decrease in LVH, echocardiographic parameters,
impaired papillary muscle function and fibrosis
were not different from untreated SHR-F. There-
fore, it appears that ACE inhibition does not
reverse the effects of failure on the functional
properties of the myocardium, at least within the
time frame of this study. Stabilization of the
clinical course of these animals may be related
to improved myocardial loading conditions
and=or to arresting the deleterious effects of
Ang II. In any case, ACE inhibitor therapy admi-
nistered to the failing SHR for a 2–4 month
period, fails to reverse pathological features of
the myocardium, improve papillary muscle func-
tion, or reduce myocardial fibrosis and stiffness.
Sen [44] has pointed out that hypertrophy may
regress with treatment but myocardium of the
post-hypertrophic heart no longer has the same
composition as it did prior to the development of
hypertrophy; the same may be true for failure.
Connective tissue remodeling of the heart is
thought to contribute to impaired performance
[10]. Reversal of fibrosis, preservation of viable
myocardium and regeneration of contractile
elements are among goals that merit considera-
tion in the treatment of the chronically failing
heart.
The studies cited above demonstrate that the
SHR serves as a useful model for testing treat-
ments which may prevent or reverse heart fail-
ure. Studies of papillary muscle function are of
particular interest because the effects of a treat-
ment on intrinsic myocardial tissue properties
may be defined. Additional studies of myocyte
preparations will help to define whether treat-
ment acts on myocytes or other constituents of
the myocardium such as the extracellular matrix.
Isolated muscle studies utilizing the SHR model
might then be useful for the assessment of other
classes of treatments. Carvedilol, a non-selective
vasodilating beta blocker with antioxidant activ-
ity administered to stroke prone SHR for 18
weeks is reported to reduce histopathologic coron-
ary artery hypertrophy, myofiber degeneration,
myocardial inflammation, microinfarction and
fibrosis [45]. A matrix metalloprotein inhibitor
has been observed to reduce collagen volume
fraction and preserve LV function in the SHHF
[46]. Iwanaga et al. [47] have determined that
cardiac endothelin-1 plays an important role in
the transition from hypertrophy to failure in salt-
sensitive hypertensive rats and that bosentan,
an endothelin receptor antagonist, attenuated
impairment of fractional shortening as deter-
mined by in vivo transthoracic echocardiography.
Although Pinto et al [48] have pointed out that
response to treatment may differ between rat
models of hypertension, studies of heart failure
prevention and reversal with differing classes of
agents in the SHR failure model are of interest.
Studies of Possible Mechanisms
Contributing to Heart Failure
Extracellular Matrix
Interstitial fibrosis is a hallmark of heart failure
associated with cardiac hypertrophy [5–7]. Fibro-
sis is also observed in the ‘‘normal’’ aging heart
[4,8,9,49]. Fibrosis increases the stiffness of the
myocardium leading to diastolic dysfunction and
contributing to heart failure [50]. The transition
to failure in the SHR is accompanied by a marked
increase in the levels of mRNA encoding extra-
cellular matrix components (for review of matrix
gene expression in the aging SHR model see
Boluyt and Bing [51]). These include fibronectin,
collagen Type I, collagen Type III [38] and osteo-
pontin [52]. Decorin and elastin have been found
to be decreased and the ratios of gelatinase A and
elastase to tissue inhibitor of metalloproteinase-4
increased in the failing SHR heart [53]. In situ
hybridization studies suggest interstitial as well
as perivascular localization of a1(I) collagen
mRNA in failing SHR hearts (Fig. 4 [54]). Fibro-
sis and stiffness were studied in the SHR with
the ACE inhibitor lisinopril, at doses that allowed
dissociation of hypertrophy and fibrosis [55].
These studies report that lisinopril could cause
regression of fibrosis and normalize myocardial
stiffness independent of LV hypertrophy. In our
experience, changes in myocardial fibrosis and
stiffness in hypertrophied hearts are small prior
to the advent of heart failure. It is also important
to distinguish between prevention and regression
of fibrosis. In studies by Brooks and coworkers
[19] using high dose captopril (2 g=L drinking
water) administered to failing SHRs, partial
regression of LVH was found without a change
in fibrosis or stiffness, or improvement of myocar-
dial function. It is clear however, that if captopril
is administered prior to heart failure, increases in
the expression of genes encoding extracellular
matrix components, fibrosis and stiffness are
attenuated, and heart failure is prevented.
Collagen alignment and type are factors that
contribute to force transmission. It has been
shown that collagen increases in SHR myocar-
dium after 40 weeks of age, and that an increase
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in type III collagen is observed. After 65 weeks of
age, there is a change in the type I to III ratio in
the SHR. It is thought that changes in myocar-
dial stiffness may be related to these changes in
collagen composition [56]. Norton et al. [57],
studying 44 week old rats, have suggested that
increased myocardial stiffness in the SHR (non-
failing) is due to enhanced collagen cross-linking.
In the failing SHR heart, the preferential expres-
sion of alternatively spliced fibronectin tran-
scripts containing EIIIA and EIIIB segments is
consistent with a wound healing response [38].
Scar tissue involved in wound healing may have
different effects on force transmission than fibrils
laid down to support stress. For example, as the
heart heals from injury after infarction, some of
the mechanical properties of the scar have been
shown to change [58].
Identification of upstream instigators of extra-
cellular matrix proliferation could provide targets
for therapies to prevent possible fibrosis mediated
deterioration of cardiac function associated with
heart failure. There is evidence that transform-
ing growth factor b1 (TGF-b1) plays an important
role in many aspects of cardiac remodeling
including the upregulation of ECM genes. In
the SHR-F hearts that exhibited markedly
increased levels of fibronectin and collagen gene
expression, a small but significant increase in
TGF-b1 was found [38]. The upregulation of
TGF-b1 observed in the failing heart suggests
that it may direct accumulation of extracellular
matrix, as it does in wound repair [59]. Treat-
ment of SHR with captopril for 2–4 months after
failure was identified results in a significant
reduction of TGF-b1 and reverses some of the
ECM changes in gene expression, but as
described, does not significantly reverse myocar-
dial fibrosis or papillary muscle stiffness [19,60].
On the other hand, it has been recently reported
that selective inhibition of the TGF-b1 family of
cytokines using a soluble type II receptor reduces
fibrosis and collagen formation in the adventitial
layer of balloon injured rat carotid arteries [61],
Fig. 4. Connective tissue deposition in the SHR-F. a) Masson’s trichrome section demonstrating extensive perivascular and
interstitial fibrosis. b) In situ hybridization demonstrates extensive subendocardial as well as focal intramyocardial a1(I) collagen
mRNA expression (adapted from [54]).
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suggesting TGF-b1 may be of importance in
mediating the connective tissue response in
some tissues, but its role in modulating of cardiac
fibrosis in the SHR has not yet been clearly
defined.
Apoptosis
In addition to fibrosis, hypertrophy and cell loss
are recognized to accompany heart failure (e.g.
[62]). In recent years considerable attention has
focused on the role of apoptosis. Apoptosis was
initially hypothesized to be a mechanism for the
transition to heart failure because of several
features; these include 1) the presence of single
myocyte loss or dropout 2) the relationship
between [Ca2þ]i and apoptosis in a variety of
tissues and abnormalities of intracellular calcium
handling in heart failure and 3) the expression of
growth factors in cardiac hypertrophy and the
relationship between trophic factors in differing
tissues, which may under some conditions lead to
growth or hypertrophy, and in others to apoptosis
[63]. The possibility that apoptosis may contri-
bute to the progression from hypertrophy to heart
failure in patients with hypertensive disease has
been reviewed [64]. To test the hypothesis that
the reduction in functional myocyte mass is due
to apoptosis in the failing SHR heart, apoptotic
cells were quantified in cross sections of myocar-
dium from WKY and non-failing and failing SHR
hearts by the nick end labeling technique [65]. An
approximately fourfold increase in the index of
apoptotic myocytes was found in LV myocardium
from the non-failing SHR compared with age
matched WKY; a further 5-fold increase in apop-
totic myocytes was found in failing SHR hearts
compared to non-failing SHR (Fig. 5 [65]). Ikeda
et al. [66] also reported an increase in non-
cardiomyocyte apoptosis in 20 month SHRs with
LV decompensation. Kajstura et al. [67] demon-
strated that angiotensin II induces apoptosis in
adult rat ventricular myocytes; these findings are
consonant with the effects of ACE inhibitor ther-
apy of the failing SHR heart where captopril
reduced the number of apoptotic cells to values
similar to those in the non-failing SHR heart [65].
Apoptosis is a relatively rapid process in which
cell surface blebbing, shrinkage and phagocytosis
occur rapidly. If we estimate an average time
period for the process of 6 hrs, calculations in
the failing SHR heart suggest approximately
50 % of myocytes may be lost over a 10 month
period, consistent with the relatively long period
of time required for the development of heart
failure in the SHR. As discussed earlier, Emanuel
et al. [29] found no differences in myocyte
contractile properties from failing and non-failing
SHR hearts and concluded that myocyte apoptosis
and remodeling of the extracellular space were
more likely responsible for the development of
heart failure. Since the dysfunction seen in fail-
ing and aging hearts are similar in a number of
respects [68], apoptosis may contribute to heart
failure seen in the elderly population. While the
roles of apoptosis and necrosis in myocardium
remains controversial, it appears likely that
myocyte loss contributes to the dysfunction of
myocardium in heart failure. Possibly, with the
loss of a critical mass of myocytes, the renin-
angiotensin-aldosterone system (RAAS) is acti-
vated and the ‘‘vicious cycle’’ culminating in
overt heart failure is initiated. A further under-
standing of the control of the myocardial cell cycle
may conceivably lead to methods which will
maintain or regenerate myocytes and possibly
stabilize or reverse failure.
Calcium Handling
The time course of intracellular calcium concen-
tration ([Ca2þ]i) reflects the integrated activities
of complex intracellular calcium handling
systems in the heart. Intracellular calcium hand-
ling events have been well summarized in a
recent review of contractile dysfunction in heart
failure [69]. In the present review, the role of
calcium handling in the SHR during the transi-
tion to failure is summarized.
Using the bioluminescent indicator aequorin,
intracellular calcium transients were recorded
from left ventricular papillary muscle prepara-
tions from age-matched WKY, SHR-NF, and
SHR-F [31]. In addition, responsiveness to
calcium and b-adrenergic stimulation with
isoproterenol were studied. Despite baseline
depression of active tension and dT=dt in SHR-F
Fig. 5. Number of apoptotic cells=100,000 nuclei in sections
of hearts from age matched (18–24 months) WKY, SHR-NF
and SHR-F and SHR-F treated (Rx) with captopril (2 g=L
drinking water for 2–4 months after the onset of failure).
* P<0.05, SHR-F vs. SHR-NF and SHR-F-Rx; **P<0.01
SHR-F vs. WKY (adapted from [65]).
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myocardium, no major differences in resting and
peak intracellular calcium concentration [Ca2þ ]i
were found (Fig. 6). Thus, depression of the active
properties of muscle preparations from failing
SHR myocardium is not explained by a corre-
sponding depression of the intracellular calcium
transient. Zaugg et al. [70], studying 8–10 month
SHR and WKY, found no differences in [Ca2þ ]i
handling parameters.
Additional studies were carried out to evaluate
mechanical responsiveness of hypertrophied and
failing SHR myocardium to inotropic stimulation.
Addition of calcium resulted in proportional
increases in peak [Ca2þ]i and mechanical func-
tion; AT and dT=dt (inotropy) in myocardium
from WKY, hypertrophied and failing SHR.
However, in studies of increasing heart rate
using the isolated buffer perfused preparation
[71], it was found that in failing SHR hearts, in
contrast to SHR-NF and WKY, the amplitude of
the calcium transient, peak pressure and dP=dt
declined at increasing heart rates. These
responses to changes in stimulation rate are
similar to findings of studies of human dilated
cardiomyopathy [72].
Isoproterenol resulted in an increase in the
calcium transient and inotropy in WKY prepara-
tions. However, despite an increase in the [Ca2þ ]i
there is little change in dT=dt and a fall in AT
after isoproterenol in both SHR groups (Fig. 7).
Findings of impaired inotropy are consistent with
well recognized reduced catecholamine respon-
siveness observed with heart failure. As has
recently been reviewed [73] impaired responsive-
ness may be due to desensitization of the b-adre-
nergic receptor in response to catecholamine
excess coincident with failure, modulation of
G proteins and=or adenyl cyclase activity. Bohm
et al. [74] studying the SHR have reported an
increase in inhibitory G proteins in the SHR
without failure which is thought to regulate
adenyl cyclase activity and contractile force.
Experimental findings suggest that impaired
inotropy to b-adrenergic stimulation in the SHR
may not involve the b-receptor, G-proteins, or
adenyl cyclase signaling. The peak of the intra-
cellular calcium transient is augmented in
response to isoproterenol and the lusitropic
response appears intact at the same time the
inotropic response is impaired (Fig. 7 [31,75]).
Overall, findings suggest that impaired
inotropy in SHR myocardium reflects a ‘‘down-
stream mechanism’’ acting in the presence of
apparently adequate cAMP production. It is not
yet clear that the specific phenomenon described
for SHR myocardium is applicable to other
models of hypertrophy and failure.
Studies of skinned muscle preparations indi-
cate that calcium sensitivity of left ventricular
preparations from the SHR is similar to WKY in
both hypertrophy and failure [76]. In the SHR-
NF relative to the WKY, maximum calcium-
activated force (Fmax) is increased. In the SHR-
F, calcium-activated force is depressed compared
with SHR-NF. Interestingly, preparations from
hypertrophied right ventricles from the SHR-F
demonstrate increased maximum calcium acti-
vated force in comparison to WKY and the non-
hypertrophied RV from SHR-NF. Thus, Fmax is
observed to be increased in hypertrophied
myocardium from both RV and LV. The increased
Fmax may be related to a change in cross-bridge
kinetics, an increase in relative force generation
per attached cross bridge or an increase in
contractile density per unit cross-sectional area
of the muscle preparation. The mechanism for the
decline in Fmax in LV preparations from failing
myocardium is unknown but may be related to
Fig. 6. Peak active tension and peak [Ca2þ ]i recorded simultaneously from isolated papillary muscle preparations from age
matched (18–24 month) WKY (n¼ 6), SHR-NF (n¼8) and SHR-F (n¼4). Peak active tension is depressed in the SHR groups relative
to WKY; particularly, the SHR-F. Peak [Ca2þ ]i does not differ among groups *P< 0.05; **P< 0.01 vs. WKY (adapted from [31]).
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extracellular factors such as a decrease in
contractile unit density, cell loss, possibly due to
apoptosis, and to an increase in collagen [28].
In summary, depressed function of LV papil-
lary muscles from the failing SHR is not
explained by a corresponding decline in the
amplitude of the calcium transient. A prolonged
calcium transient is observed in both hypertro-
phied and failing myocardium from the SHR.
Perfused heart studies suggest that at the stage
of heart failure, impaired calcium cycling in asso-
ciation with increased heart rates may contribute
to systolic and diastolic dysfunction. While myo-
filament calcium responsiveness appears normal
and papillary muscles from failing myocardium
remain normally responsive to calcium mediated
inotropic stimulation, inotropy in response to
b-adrenergic stimulation is impaired in both
SHR-NF and SHR-F despite appropriate
augmentation of the calcium transient and of
lusitropy. It is presently unclear whether the
specific mechanism(s) responsible for impaired
inotropy to catecholamine stimulation is necessa-
rily related to the cause(s) of failure in the SHR.
Energetics
One of the consequences of ventricular pressure
overload is the requirement for more energy to
meet the demands of an increased workload.
Rakusan et al. [77] (1992) have shown that LV
pressure overload hypertrophy in adult human
myocardium is associated with failure of capillary
angiogenesis. Medial hypertrophy of small coron-
ary vessels associated with increased wall thick-
ness were considered to explain impaired
coronary flow and decreased coronary reserve in
hypertensive LVH [78]. Engelmann et al. [79]
reported a decrease in the LV capillary density
in the SHR at 6 months. A number of investiga-
tors have reported decreases in CrP levels in the
aging SHR heart [80–82]. Bittl and Ingwall [83]
reported a 50 % decrease in Cr kinase activity in
the 18 month SHR relative to age-matched WKY.
O’Donnell et al. [84] observed that a decline in
PCr and creatine signals the transition to failure
in the SHHF. Thus, among possibilities, decreased
microvascular blood flow might impair oxygen
delivery, decrease the pool of high energy inter-
mediates and performance of the hypertrophied
Fig. 7. Aequorin light signals and isometric mechanical activity recorded simultaneously from isolated papillary muscle
preparations obtained from aged (18–24 months) WKY, SHR-NF and SHR-F. It can be seen that in the control state (C), the calcium
transient is prolonged in both SHR preparations relative to WKY. Isoproterenol 10 6M (ISO) increases peak light in all groups. Peak
isometric tension falls considerably in both SHR groups while little decline is seen in WKY. Temperature 30

C, stimulation rate
20=min (adapted from [31]).
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heart, contributing to heart failure. To examine
the role of oxygen delivery on impaired function
seen in the failing SHR heart, the relation
between function and oxygen consumption was
studied in 18–24 month control (WKY), hypertro-
phied, and failing SHR hearts [85]. Utilizing the
isolated perfused isovolumic (balloon in LV) heart
preparation, it was found that at constant intra-
ventricular volume, systolic pressure develop-
ment was greatest in the SHR-NF and lowest in
the SHR-F group. Correcting for wall thickness,
midwall stress development was greatest in the
WKY and lowest in the SHR-F heart, consistent
with impairment of function observed in papillary
muscle studies from aged and failing SHR hearts.
Increasing perfusion pressure did not reverse
depression of systolic stress in the SHR-F.
Myocardial oxygen consumption per gram LV
was lowest in the SHR-F group. Correcting for
stress development, however, MVO2 was lowest in
the WKY and greatest in the SHR-F. Thus, the
oxygen cost of stress development was greatest in
the SHR-F (Fig. 8). An increase in the oxygen cost
of stress development has also been observed in
papillary muscle preparations from the pulmon-
ary artery banded cat [86], which was found to be
due to nonphosphorylating mitochondrial respira-
tion [87]. Increased ‘‘economy of contraction’’
based on myothermal data from hypertrophied
papillary muscles [88,89] is thought related to
Fig. 8. Systolic Stress (a) and myocardial consumption (b) determined from isolated (balloon in ventricle) buffer perfused heart
preparations. Age matched (18–24 months) WKY (n¼13), SHR-NF (n¼8) and SHR-F (n¼8) are compared. Systolic stress and
myocardial oxygen consumption are decreased in the SHR-F group relative to WKY and SHR-NF. Increasing perfusion pressure
from 100 to 130 mmHg fails to restore parameters in the SHR-F group to values seen in non-failing hearts. The relation between
myocardial consumption and systolic stress (c) is shifted to the left in the SHR-F (solid squares) and SHR-NF (open squares) groups
demonstrating an increased oxygen cost of stress development in the SHR groups relative to age-matched WKY (open circles);
particularly the SHR-F. (*P<0.05; **P< 0.01 respectively; perfusion pressure 130 vs. 100 mmHg) (adapted from [85]).
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an adaptive shift in myosin isozymes [90]. Thus,
improved energetic efficiency based on myother-
mal data appears to be offset by decreased effi-
ciency based on oxygen consumption data; the
latter may be a factor contributing to the observed
decrease in PCr.
In perfused hearts, no lactate was produced by
any of the groups in the baseline state [85].
Lactate was produced, however, during graded
hypoxia; reducing perfusate PO2 from 95 to 50,
25 and 0 (%) resulted in a progressive fall in
systolic stress and MVO2 while lactate was
observed to increase progressively in all groups.
Since isolated heart preparations from the SHR-F
produces lactate during hypoxia but not in the
baseline state, these data suggest that the base-
line impairment of function observed in the SHR-
F, which is not associated with lactate production,
is not due to hypoxia—or that hypoxia=ischemia
are present without lactate production (‘hibernat-
ing myocardium’ [91]).
Tolerance of isolated muscle preparations to
hypoxia was studied comparing 6 and 18 month
SHR and age matched WKY [92]. Papillary
muscles from 18 month SHR had the lowest
CrP and adenylate energy charge which may
explain increased contracture and depressed
tension development when carbohydrate is
limited (5.5 mM glucose) after protracted
(60 min) hypoxia. Although performance of
hypoxic papillary muscles is improved in the
presence of high glucose (20 mM glucose [93]),
performance of perfused hearts during hypoxia
is not associated with augmented lactate produc-
tion (see earlier). These data suggest that while
ischemia or hypoxia does not appear to be respon-
sible for impaired baseline stress development
in the failing SHR, hypertrophied and failing
myocardium appear to have impaired tolerance
to prolonged hypoxia. Findings may be relevant
to cardiac preservation where it has been noted
that hypertrophied hearts exhibit decreased
tolerance to prolonged arrest [94].
Microtubular Polymerization
Based on the studies of Tsutsui et al. [95,96], who
studied right ventricular preparations from cats,
it was suggested that microtubular polymeriza-
tion associated with hypertrophy might act as
an internal load impairing the performance of
cardiac muscle and contributing to heart failure.
Lysing the microtubules with colchicine was
observed to improve the performance of cardiac
myocytes from hypertrophied hearts. Accord-
ingly, in an attempt to prevent heart failure in
the SHR, colchicine (1 mg=L) was added to the
drinking water of 12 month old SHR and WKY
until 24 months of age, or the appearance of
clinical manifestations of heart failure [35]. No
differences in the clinico-pathological manifesta-
tions of heart failure were found between colchi-
cine treated and untreated SHR. Likewise, the
mechanical performance of papillary muscle
preparations from these animals was not
improved. The direct effects of colchicine were
also studied in papillary muscle preparations
from control, hypertrophied, and failing SHR
hearts [97]. Colchicine at concentrations from
104–106 M failed to augment the performance
of preparations from hypertrophied and failing
SHR hearts. Thus, studies utilizing colchicine fail
to suggest a role for microtubular polymerization
in the depressed function found in the failing
SHR heart. As pointed out by Tsutsui et al. [98],
differences between their findings [95,96] and
those of others may reflect variables such as the
animal species, the ventricle studied, and the
stage of hypertrophy=failure.
Summary and Future Directions
The SHR has been found to be a useful model in
which to study the combined effects of aging and
hypertension on the heart. A valuable aspect of
studies in the SHR is that long term studies over
the course of its lifespan are feasible from a
practical perspective. While there are a number
of points for questioning the SHR as a suitable
model of human hypertension, the clinical course
of animals and response to treatment appears
similar in a number of aspects to those observed
in humans. The effectiveness of ACE inhibitors
and angiotensin receptor blockers in both the
SHR and humans support the SHR as a model
for pilot studies of potential treatments. However,
it remains to be determined which conclusions
derived from this model regarding specific treat-
ments and the mechanism of heart failure are
applicable to humans.
Studies have revealed that the SHR develops
heart failure between 18–24 months of age. Fail-
ure is associated with recognized clinical, patho-
logical, and hemodynamic findings, as well as
myocardial fibrosis and impairment of intrinsic
myocardial function. Virtually all manifestations
of failure and associated changes in gene expres-
sion can be prevented by inhibition of production-
or blocking the effects of Ang II, a component of
the neurohormonal system well recognized to be
activated in association with heart failure. Find-
ings are consistent with the concept that the renin
angiotensin aldosterone system (RAAS) has
evolved to support the circulation in a young,
generally healthy population without cardiovas-
cular dysfunction but is maladaptive in the aged,
failing heart. Findings in the SHR demonstrate
that treatment with ACE inhibitor or AT1 blocker
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prior to heart failure is able to prevent not only
failure but intrinsic myocardial tissue dysfunc-
tion; treatment after failure demonstrates clinical
improvement, as seen in humans, but impairment
of intrinsic myocardial function is not reversed.
Thus, a practical goal of studies in animals such
as the SHR is to improve impaired myocardial
function or prevent dysfunction.
Some of the possible mechanisms directly
contributing to failure in the SHR have been
briefly reviewed. To further understand the
basis for heart failure, a common approach in
recent years has been to measure changes in
transcripts encoding proteins thought to play a
role in heart failure. In addition to studying early
changes in traditional genes, comparison of gene
expression using the techniques of subtractive
hybridization [99] and differential display
[52,100,101] suggests a role for previously unsus-
pected genes and pathways which may be related
to the genesis of heart failure. Consistent with
this approach, a number of laboratories are
comparing arrays of transcripts using gene chip
technology. It should be pointed out that unlike
subtractive hybridization and differential display,
only changes in selected transcripts will be found
using this technique, and that possibly important
unsuspected genes will not be discovered or
evaluated. Despite this limitation, the potential
of this approach to identify novel mechanistic
contributors to heart failure is excellent.
While Ang II plays a major role in the transi-
tion to overt heart failure in the SHR, specific
mechanisms by which Ang II and other neuro-
hormones remodel the myocardium remain under
study. A further question of major interest and
importance, not yet well studied in the SHR
model, is the role of factor(s) which precede and
lead to neurohumoral activation. It is not clear
whether the mechanisms responsible for overt
failure are the same as those leading to the
point where the neurohormonal system is acti-
vated. To examine this question, strategies will
have to be developed to study the compensated
hypertrophied heart for mechanisms which trig-
ger neurohormonal activation initiating the
vicious cycle culminating in overt heart failure.
Animals models with a predictable clinico-patho-
logic course such as the SHR will provide an
important resource for advancing our under-
standing of the genesis of heart failure in the
aging hypertrophied heart.
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